Tirasemtiv - Cytokinetics

Drug Profile

Tirasemtiv - Cytokinetics

Alternative Names: CK-2017357; CK-357

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokinetics
  • Class 2 ring heterocyclic compounds; Alkynes; Imidazolidines; Pyrazines; Small molecules
  • Mechanism of Action Troponin tropomyosin complex stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Amyotrophic lateral sclerosis; Muscle fatigue; Myasthenia gravis
  • No development reported Spinal muscular atrophy

Most Recent Events

  • 21 Nov 2017 Suspended - Phase-II for Muscle fatigue in USA (PO)
  • 21 Nov 2017 Suspended - Phase-II for Myasthenia gravis in USA (PO)
  • 21 Nov 2017 Suspended - Phase-III for Amyotrophic lateral sclerosis in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top